Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A

Science Signaling

Volumn 4, Issue 171, 2011, Pages

  Embry, Chelsea A ^a   Franchi, Luigi ^b   Nunez, Gabriel ^b   Mitchell, Thomas C ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHORYL LIPID A; PROTEIN PRECURSOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; CARRIER PROTEIN; CIAS1 PROTEIN, MOUSE; DRUG DERIVATIVE; IMMUNOLOGICAL ADJUVANT; LIPID A; MYD88 PROTEIN, MOUSE; TICAM 1 PROTEIN, MOUSE; TICAM-1 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECT; DRUG POTENTIATION; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT;

ADAPTIVE IMMUNITY; ADAPTOR PROTEINS, VESICULAR TRANSPORT; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CARRIER PROTEINS; CASPASE 1; INFLAMMASOMES; INTERLEUKIN-1BETA; LIPID A; MICE; MICE, KNOCKOUT; MODELS, IMMUNOLOGICAL; MYELOID DIFFERENTIATION FACTOR 88; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 79955681975     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2001486     Document Type: Article

References (57)

1. E. M. Pålsson-McDermott, L. A. O'Neill, Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 113, 153-162 (2004) (Pubitemid 39312442)
2. D. H. Persing, R. N. Coler, M. J. Lacy, D. A. Johnson, J. R. Baldridge, R. M. Hershberg, S. G. Reed, Taking toll: Lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 10, S32-S37 (2002)
3. E. Ribi, Beneficial modification of the endotoxin molecule. J. Biol. Response Mod. 3, 1-9 (1984) (Pubitemid 14172083)
4. A. M. Didierlaurent, S.Morel, L. Lockman, S. L. Giannini, M. Bisteau, H. Carlsen, A. Kielland, O. Vosters, N. Vanderheyde, F. Schiavetti, D. Larocque, M. Van Mechelen, N. Garcon, AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183, 6186-6197 (2009)
5. K. Okemoto, K. Kawasaki, K. Hanada, M. Miura, M. Nishijima, A potent adjuvant monophosphoryl lipid A triggers various immune responses, but not secretion of IL-1β or activation of caspase-1. J. Immunol. 176, 1203-1208 (2006) (Pubitemid 43099724)
6. V. Mata-Haro, C. Cekic, M. Martin, P. M. Chilton, C. R. Casella, T. C. Mitchell, The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316, 1628-1632 (2007) (Pubitemid 46982038)
7. C. Cekic, C. R. Casella, C. A. Eaves, A. Matsuzawa, H. Ichijo, T. C. Mitchell, Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A. J. Biol. Chem. 284, 31982-31991 (2009)
8. F. G. Bauernfeind, G. Horvath, A. Stutz, E. S. Alnemri, K. MacDonald, D. Speert, T. Fernandes-Alnemri, J. Wu, B. G. Monks, K. A. Fitzgerald, V. Hornung, E. Latz, Cutting edge: NF-kB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183, 787-791 (2009)
9. L. Franchi, T. Eigenbrod, G. Núñez, Cutting edge: TNF-a mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J. Immunol. 183, 792-796 (2009)
10. L. Franchi, T. Eigenbrod, R. Muñoz-Planillo, G. Nuñez, The inflammasome: A caspase-1- activation platform that regulates immune responses and disease pathogenesis. Nat. Immunol. 10, 241-247 (2009)
11. T. Fernandes-Alnemri, J. Wu, J. W. Yu, P. Datta, B. Miller, W. Jankowski, S. Rosenberg, J. Zhang, E. S. Alnemri, The pyroptosome: A supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 14, 1590-1604 (2007) (Pubitemid 47278845)
12. N. B. Bryan, A. Dorfleutner, Y. Rojanasakul, C. Stehlik, Activation of inflammasomes requires intracellular redistribution of the apoptotic speck-like protein containing a caspase recruitment domain. J. Immunol. 182, 3173-3182 (2009)
13. N. A. Thornberry, H. G. Bull, J. R. Calaycay, K. T. Chapman, A. D. Howard, M. J. Kostura, D. K. Miller, S. M. Molineaux, J. R. Weidner, J. Aunins, K. O. Elliston, J. M. Ayala, F. J. Casano, J. Chin, G. J.-F. Ding, L. A. Egger, E. P. Gaffney, G. Limjuco, O. C. Palyha, S. M. Raju, A. M. Rolando, J. P. Salley, T.-T. Yamin, T. D. Lee, J. E. Shively, M. MacCross, R. A. Mumford, J. A. Schmidt, M. J. Tocci, A novel heterodimeric cysteine protease is required for interleukin-1b processing in monocytes. Nature 356, 768-774 (1992)
14. B. K. Davis, J. P. Ting, NLRP3 has a sweet tooth. Nat. Immunol. 11, 105-106 (2010)
15. I. Mitroulis, P. Skendros, K. Ritis, Targeting IL-1β in disease; the expanding role of NLRP3 inflammasome. Eur. J. Intern. Med. 21, 157-163 (2010)
16. S. Suzuki, L. H. Toledo-Pereyra, Interleukin 1 and tumor necrosis factor production as the initial stimulants of liver ischemia and reperfusion injury. J. Surg. Res. 57, 253-258 (1994) (Pubitemid 24262396)
17. Y. Tang, B. Li, N. Wang, Y. Xie, L. Wang, Q. Yuan, F. Zhang, J. Qin, Z. Peng, W. Ning, L. Wang, G. Hu, J. Li, L. Tao, Fluorofenidone protects mice from lethal endotoxemia through the inhibition of TNF-a and IL-1β release. Int. Immunopharmacol. 10, 580-583 (2010)
18. R. Torres, L. Macdonald, S. D. Croll, J. Reinhardt, A. Dore, S. Stevens, D. M. Hylton, J. S. Rudge, R. Liu-Bryan, R. A. Terkeltaub, G. D. Yancopoulos, A. J. Murphy, Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann. Rheum. Dis. 68, 1602-1608 (2009).
19. R. Torres, L. Macdonald, S. D. Croll, J. Reinhardt, A. Dore, S. Stevens, D. M. Hylton, J. S. Rudge, R. Liu-Bryan, R. A. Terkeltaub, G. D. Yancopoulos, A. J. Murphy, Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann. Rheum. Dis. 68, 1602-1608 (2009). 19. E. Voronov, M. Dayan, H. Zinger, L. Gayvoronsky, J. P. Lin, Y. Iwakura, R. N. Apte, E. Mozes, IL-1β-deficient mice are resistant to induction of experimental SLE. Eur. Cytokine Netw. 17, 109-116 (2006)
20. Y. Yamasaki, N. Matsuura, H. Shozuhara, H. Onodera, Y. Itoyama, K. Kogure, Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke 26, 676-680 (1995)
21. C. Maldonado, W. K. Stadelmann, S. Ramirez, E. E. Quan, J. H. Barker, Preconditioning of latissimus dorsi muscle flaps with monophosphoryl lipid A. Plast. Reconstr. Surg. 111, 267-274 (2003) (Pubitemid 36015189)
22. R. Sharony, I. Frolkis, D. Froylich, S. M. Wildhirt, I. Shapira, B. Reichart, N. Nesher, G. Uretzky, Pharmacological preconditioning with monophosphoryl lipid A improves post ischemic diastolic function and modifies TNF-a synthesis. Eur. J. Cardiothorac. Surg. 27, 501-507 (2005) (Pubitemid 40312362)
23. L. Xiuhua, W. Xudong, H. Yue, T. Chaoshu, S. Jingyi, Signaling pathway of cardioprotection induced by monophosphoryl lipid A in rabbit myocardium. Pathophysiology 8, 193-196 (2002) (Pubitemid 34597211)
24. N. Yamashita, S. Hoshida, K. Otsu, N. Taniguchi, T. Kuzuya, M. Hori, Monophosphoryl lipid A provides biphasic cardioprotection against ischaemia-reperfusion injury in rat hearts. Br. J. Pharmacol. 128, 412-418 (1999) (Pubitemid 29458601)
25. T. Yoshida, R. M. Engelman, D. T. Engelman, J. A. Rousou, N. Maulik, M. Sato, G. T. Elliott, D. K. Das, Preconditioning of swine heart with monophosphoryl lipid A improves myocardial preservation. Ann. Thorac. Surg. 70, 895-900 (2000)
26. H. Q. Zhu, J. L. Jiang, R. Lu, X. H. Zhang, H. W. Deng, Y. J. Li, The protective effects of monophosphoryl lipid A on the ischemic myocardium and endothelium in rats. Cardiovasc. Drugs Ther. 17, 311-318 (2003) (Pubitemid 37500182)
27. Y. Shikama, T. Kuroishi, Y. Nagai, Y. Iwakura, H. Shimauchi, H. Takada, S. Sugawara, Y. Endo, Muramyldipeptide augments the actions of lipopolysaccharide in mice by stimulating macrophages to produce pro-IL-1β and by down-regulation of the suppressor of cytokine signaling 1 (SOCS1). Innate Immun. 17, 3-15 (2011)
28. L. C. Hsu, S. R. Ali, S. McGillivray, P. H. Tseng, S. Mariathasan, E.W. Humke, L. Eckmann, J. J. Powell, V. Nizet, V. M. Dixit, M. Karin, A NOD2-NALP1 complex mediates caspase- 1-dependent IL-1β secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc. Natl. Acad. Sci. U.S.A. 105, 7803-7808 (2008) (Pubitemid 351872719)
29. G. Ferwerda, M. Kramer, D. de Jong, A. Piccini, L. A. Joosten, I. Devesaginer, S. E. Girardin, G. J. Adema, J. W. van der Meer, B. J. Kullberg, A. Rubartelli, M. G. Netea, Engagement of NOD2 has a dual effect on proIL-1β mRNA transcription and secretion of bioactive IL-1β. Eur. J. Immunol. 38, 184-191 (2008)
30. F. Vacheron, M. Guenounou, C. Nauciel, Induction of interleukin 1 secretion by adjuvantactive peptidoglycans. Infect. Immun. 42, 1049-1054 (1983) (Pubitemid 14244376)
31. M. Yamamoto, K. Yaginuma, H. Tsutsui, J. Sagara, X. Guan, E. Seki, K. Yasuda, M. Yamamoto, S. Akira, K. Nakanishi, T. Noda, S. Taniguchi, ASC is essential for LPSinduced activation of procaspase-1 independently of TLR-associated signal adaptor molecules. Genes Cells 9, 1055-1067 (2004) (Pubitemid 39467978)
32. J. Harder, L. Franchi, R. Munoz-Planillo, J. H. Park, T. Reimer, G. Nunez, Activation of the Nlrp3 inflammasome by Streptococcus pyogenes requires streptolysin O and NF-kB activation but proceeds independently of TLR signaling and P2X7 receptor. J. Immunol. 183, 5823-5829 (2009).
33. R. Muñoz-Planillo, L. Franchi, L. S. Miller, G. Núñez, A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the Nlrp3 inflammasome. J. Immunol. 183, 3942-3948 (2009)
34. C. Toma, N. Higa, Y. Koizumi, N. Nakasone, Y. Ogura, A. J. McCoy, L. Franchi, S. Uematsu, J. Sagara, S. Taniguchi, H. Tsutsui, S. Akira, J. Tschopp, G. Nunez, T. Suzuki, Pathogenic Vibrio activate NLRP3 inflammasome via cytotoxins and TLR/nucleotide-binding oligomerization domain-mediated NF-kB signaling. J. Immunol. 184, 5287-5297 (2010)
35. D. J. Taxman, J. Zhang, C. Champagne, D. T. Bergstralh, H. A. Iocca, J. D. Lich, J. P. Ting, Cutting edge: ASC mediates the induction of multiple cytokines by Porphyromonas gingivalis via caspase-1-dependent and -independent pathways. J. Immunol. 177, 4252-4256 (2006) (Pubitemid 44469750)
36. T. Kawai, O. Adachi, T. Ogawa, K. Takeda, S. Akira, Unresponsiveness of MyD88- deficient mice to endotoxin. Immunity 11, 115-122 (1999) (Pubitemid 29359962)
37. P. Pelegrin, C. Barroso-Gutierrez, A. Surprenant, P2X7 receptor differentially couples to distinct release pathways for IL-1β in mouse macrophage. J. Immunol. 180, 7147-7157 (2008)
38. M. T. Huang, D. J. Taxman, E. A. Holley-Guthrie, C. B. Moore, S. B. Willingham, V. Madden, R. K. Parsons, G. L. Featherstone, R. R. Arnold, B. P. O'Connor, J. P. Ting, Critical role of apoptotic speck protein containing a caspase recruitment domain (ASC) and NLRP3 in causing necrosis and ASC speck formation induced by Porphyromonas gingivalis in human cells. J. Immunol. 182, 2395-2404 (2009)
39. J. V. Rajan, S. E. Warren, E. A. Miao, A. Aderem, Activation of the NLRP3 inflammasome by intracellular poly I:C. FEBS Lett. 584, 4627-4632 (2010)
40. H. Li, S. B. Willingham, J. P. Ting, F. Re, Cutting edge: Inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J. Immunol. 181, 17-21 (2008)
41. M. Kool, V. Pétrilli, T. De Smedt, A. Rolaz, H. Hammad, M. van Nimwegen, I. M. Bergen, R. Castillo, B. N. Lambrecht, J. Tschopp, Cutting edge: Alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J. Immunol. 181, 3755-3759 (2008)
42. L. Franchi, G. Núñez, The Nlrp3 inflammasome is critical for aluminium hydroxidemediated IL-1β secretion but dispensable for adjuvant activity. Eur. J. Immunol. 38, 2085-2089 (2008)
43. R. Spreafico, P. Ricciardi-Castagnoli, A. Mortellaro, The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. Eur. J. Immunol. 40, 638-642 (2010).
44. G. Guarda, C. Dostert, F. Staehli, K. Cabalzar, R. Castillo, A. Tardivel, P. Schneider, J. Tschopp, T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature 460, 269-273 (2009)
45. T. Saitoh, N. Fujita, M. H. Jang, S. Uematsu, B. G. Yang, T. Satoh, H. Omori, T. Noda, N. Yamamoto, M. Komatsu, K. Tanaka, T. Kawai, T. Tsujimura, O. Takeuchi, T. Yoshimori, S. Akira, Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1β production. Nature 456, 264-268 (2008)
46. E. Naik, V. M. Dixit, Modulation of inflammasome activity for the treatment of autoinflammatory disorders. J. Clin. Immunol. 30, 485-490 (2010)
47. G. P. Cook, S. Savic, M. Wittmann, M. F. McDermott, The NLRP3 inflammasome, a target for therapy in diverse disease states. Eur. J. Immunol. 40, 631-634 (2010)
48. A. A. Wanderer, Rationale for IL-1β targeted therapy for ischemia-reperfusion induced pulmonary and other complications in sickle cell disease. J. Pediatr. Hematol. Oncol. 31, 537-538 (2009).
49. R. Terkeltaub, J. S. Sundy, H. R. Schumacher, F. Murphy, S. Bookbinder, S. Biedermann, R. Wu, S. Mellis, A. Radin, The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann. Rheum. Dis. 68, 1613-1617 (2009)
50. C. A. Dinarello, Interleukin-1β and the autoinflammatory diseases. N. Engl. J. Med. 360, 2467-2470 (2009).
51. C. A. Wy, M. Goto, R. I. Young, T. F. Myers, J. Muraskas, Prophylactic treatment of endotoxic shock with monophosphoryl lipid A in newborn rats. Biol. Neonate 77, 191-195 (2000) (Pubitemid 30166969)
52. C. Hamilton-Davies, A. R. Webb, Monophosphoryl lipid A and endotoxin tolerance. Crit. Care Med. 23, 1789-1790 (1995)
53. M. E. Astiz, E. C. Rackow, J. G. Still, S. T. Howell, A. Cato, K. B. Von Eschen, J. T. Ulrich, J. A. Rudbach, G. McMahon, R. Vargas, W. Stern, Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: A prospective, double-blind, randomized, controlled trial. Crit. Care Med. 23, 9-17 (1995)
54. G. L. Gustafson, M. J. Rhodes, T. Hegel, Monophosphoryl lipid A as a prophylactic for sepsis and septic shock. Prog. Clin. Biol. Res. 392, 567-579 (1995)
55. O. Lüderitz, A. M. Staub, O.Westphal, Immunochemistry of O and R antigens of Salmonella and related Enterobacteriaceae. Bacteriol. Rev. 30, 192-255 (1966)
56. S. K. Biswas, E. Lopez-Collazo, Endotoxin tolerance: New mechanisms, molecules and clinical significance. Trends Immunol. 30, 475-487 (2009)
57. Acknowledgments: We thank C. Casella, P. Chilton, and M. Martin for their expert advice; D. Hadel for animal husbandry and genotyping; R. Higashi and B. Bogdonov for mass spectrometry analysis of lipid A structures; and E. Yolcu, C. Daep, and E. Roy for confocal microscopy assistance. Funding: This study was funded by the American Heart Association (predoctoral grant to C.A.E.), the Crohn's and Colitis Foundation of America (Career Development Award to L.F.), and the NIH (R01 AI071047 to T.C.M. and R01 1AR052756/AI063331 to G.N.). Author contributions: C.A.E. performed all experimentation and wrote the preliminary manuscript draft. C.A.E., L.F., G.N., and T.C.M. contributed to experimental design and interpretation and manuscript revision. Competing interests: The authors declare that they have no competing interests.